France Drug Delivery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

The French drug delivery devices market is anticipated to expand at a CAGR of 5.2% over the forecast period.

With the emergence of the COVID-19 pandemic, most pharmaceutical companies and governments have been/are working to provide adequate medical therapy to COVID-19 patients, and drug delivery devices are likely to play an essential role in this context. For example, large-scale vaccination programs are being implemented worldwide to immunize people against the SARS-COV-2 virus. However, many companies are still working on more efficient ways of delivering COVID-19 therapeutics to patients and are investing heavily in it, which is expected to impact the drug delivery market significantly. For instance, in January 2022, the BioMAP research team from the Infectiology and Public Health (ISP) joint research unit run by INRAE and the Université de Tours developed a protein vaccine candidate for nasal administration to project against COVID-19 blocking all transmission of the virus. The Ministry of Higher Education, Research, and innovation supports the project and is accompanied by the National Agency for AIDS Research (ANRS). As a result, COVID-19 was predicted to impact the drug delivery market's growth substantially. Additionally, the market is anticipated to resume its rise during the projection period as more research and development is undertaken on COVID-19 vaccines and all restrictions are removed.

The rising prevalence of chronic diseases, technological advancements, and growth in the biologics market are some key factors driving the development of the France drug delivery devices market. Many disorders, including cardiovascular disease and diabetes, can benefit from targeted drug administration. The most important application of targeted medication delivery is the treatment of malignant tumors. As a result, the increasing prevalence of these disorders is likely to drive market expansion throughout the forecast period. For instance, the high burden of cancer can be explained by the latest statistics provided by the International Agency for Research on Cancer published GLOBOCAN 2020 report, which stated that in 2020, there were an estimated 467,965 new cancer cases diagnosed, where the male population accounted for 260,169 cases followed by female population with 207,796 cases. This shows a high burden of cancer among the target population. As a result, the population's increasing reliance on various drug types, including chemotherapy and intravenous therapy, is projected to fuel the market's expansion.

Thus, all the mentioned factors are expected to boost market growth over the forecast period. However, the risk of needlestick injury may restrain market growth over the forecast period.

France Drug Delivery Devices Market Trends

Diabetes Segment is Estimated to Witness Healthy Growth over the Forecast Period

The diabetes segment is driven by the increasing prevalence of diabetes in France and the product launches by the key market players. According to the International Diabetes Federation, in February 2022, the diabetic majority was 8.6%, with 3,942,900 adult diabetics in France in 2020. Additionally, according to the World Health Organization (WHO) May 2021, about a million are diagnosed with diabetes in France. The prevalence of diabetes is growing among all ages in France, which can be attributed to the growing obese population, unhealthy diets, and sedentary lifestyles. Thus, the rising prevalence of diabetes and obesity, growing awareness regarding diabetic care, healthcare expenditure, and technological advancements are a few factors that further drive the segment in France.

Furthermore, strategies adopted by the key market players, such as product launches, mergers, acquisitions, and partnerships, are likely to support market growth. For instance, in April 2021, BioCorp and Roche Diabetes Care France reported the launch of the Mallya smart insulin pen device in France. The device is designed to automatically gather insulin data (dose, date, and time) and upload it to Roche's Gluci-Chek application to ensure qualified information on which the patient can depend and the clinician may utilize to make informed clinical decisions. Additionally, in November 2021, Sanofi and Roche joined forces in France, teaming up to drive the adoption of a connected add-on for disposable insulin pens. The partners will jointly develop a scientific program for physicians and retail pharmacists around the Biocorp product. Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.

Infectious Diseases is Expected to Hold Significant Share During the Forecast Period

Pathogenic microorganisms, such as bacteria, viruses, parasites, or fungi, cause infectious diseases. These diseases can spread directly or indirectly from one person to another. Common contagious diseases are Streptococcal Pharyngitis, urinary tract infections (caused by bacteria), HIV/AIDS, the common cold (caused by a virus), Athlete's foot (a common fungus), etc.

With the increasing burden of infectious diseases in France, the market is expected to project growth over the forecast period. According to the UNAIDS factsheet, in 2021, there were 190,000 HIV-positive persons in France. In 2021, the number of new HIV infections was 5,800. Regarding gender, men are more impacted than women, and it is most common among people aged 55 to 64. The region of Paris, known as Île-de-France, has the highest rate of diagnoses. Thus, the country's growing prevalence of infectious diseases is expected to increase demand for drug-delivery devices, thereby boosting the market's growth over the forecast period.

Additionally, various initiatives the market players take are likely to support the market's growth over the forecast period. For instance, in November 2022, Aptar Pharma, a drug delivery company, completed the first phase of its announced USD 180 million expansion initiative to satisfy expanding customer capacity needs for injectable system solutions.

Thus, all factors above such as the growing prevalence of infectious diseases and strategic initiatives by market players, are expected to boost the market in the country over the forecast period.

France Drug Delivery Devices Market Competitor Analysis

The French drug delivery devices Market is moderately competitive and consists of several major players. Some companies currently dominating the market are Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Inc, Becton, Dickinson and Company, and 3M, among others.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.